Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : GBS-NN/NN2,Aluminum
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : EQT Life Sciences
Deal Size : $56.8 million
Deal Type : Financing
Details : This financing will enable MinervaX to progress its novel GBS vaccine GBS-NN/NN2, towards Phase III clinical trials in 2024. The Company is currently progressing two Phase II clinical trials in 470 pregnant persons across Denmark, United Kingdom, Uganda ...
Product Name : GBS-NN/NN2
Product Type : Vaccine
Upfront Cash : Undisclosed
November 10, 2023
Lead Product(s) : GBS-NN/NN2,Aluminum
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : EQT Life Sciences
Deal Size : $56.8 million
Deal Type : Financing
Lead Product(s) : GBS-NN/NN2,GBS/NN2
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : European and Developing Countries Clinical Trials Partnership
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : GBS-NN/NN2 is a novel innovative, adjuvanted protein Vaccine which are based on traditional capsular polysaccharide (CPS) conjugate technology and investigated for the treatment of Group B Streptococcus.
Product Name : GBS-NN/NN2
Product Type : Vaccine
Upfront Cash : Inapplicable
June 27, 2023
Lead Product(s) : GBS-NN/NN2,GBS/NN2
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : European and Developing Countries Clinical Trials Partnership
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : GBS-NN/NN2
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The process is designed to facilitate the development of investigational treatment GBS-NN/NN2, that demonstrate the potential to address unmet medical needs in serious or life-threatening conditions.
Product Name : GBS-NN/NN2
Product Type : Vaccine
Upfront Cash : Inapplicable
May 01, 2023
Lead Product(s) : GBS-NN/NN2
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : GBS-NN/NN2
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : REPAIR Impact Fund
Deal Size : $23.4 million
Deal Type : Financing
Details : The GBS-NN/NN2 vaccine consists of two fusion proteins consisting of either AlpCN and RibN (GBS-NN) or Alp1N and Alp2/3N (GBS-NN2), formulated with AlOH adjuvant.
Product Name : GBS-NN/NN2
Product Type : Vaccine
Upfront Cash : Undisclosed
December 15, 2022
Lead Product(s) : GBS-NN/NN2
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : REPAIR Impact Fund
Deal Size : $23.4 million
Deal Type : Financing
Lead Product(s) : GBS-NN
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
MinervaX Provides Clinical and Leadership Update
Details : Group B Streptococcal vaccine based on traditional capsular polysaccharide (CPS) conjugate technology consists of two fusion proteins consisting of either AlpCN and RibN (GBS-NN) or Alp1N and Alp2/3N (GBS-NN2), formulated with AlOH adjuvant.
Product Name : GBS-NN
Product Type : Vaccine
Upfront Cash : Inapplicable
July 10, 2021
Lead Product(s) : GBS-NN
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : GBS-NN
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Sanofi
Deal Size : $57.0 million
Deal Type : Series B Financing
Details : Proceeds will advance the clinical development of MinervaX’s novel GBS vaccine through Phase II clinical trials, as well as manufacturing and regulatory preparation for Phase III.
Product Name : GBS-NN
Product Type : Vaccine
Upfront Cash : Undisclosed
December 15, 2020
Lead Product(s) : GBS-NN
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Sanofi
Deal Size : $57.0 million
Deal Type : Series B Financing